6MWD was recorded before and after 16
| Property | Description | Notes |
|---|---|---|
| Mechanism of Action | PDE5 inhibitor that increases blood flow in genital regions | Used off-label for sexual dysfunction |
| Bioavailability | Approximately 80% | Oral administration |
| Duration of Effect | Up to 36 hours | Longer than Sildenafil |
| Half-life | About 17.5 hours | Affects dosing frequency |
| Metabolism | Primarily via liver CYP3A4 | Precaution in liver impairment |
weeks of treatment with tadalafil or placebo
Hormone levels—especially estrogen and testosterone—can fluctuate during this time. If your symptoms sound familiar, it may not just be a blood flow issue. Hormonal shifts could be playing a central role. Before jumping to conclusions, it's worth using a free AI-powered symptom checker specifically for Peri-/Post-Menopausal Symptoms to better understand whether hormonal changes might be at the root of what you're experiencing. Understanding the root cause is key before considering medications like tadalafil.
Before starting tadalafil, your doctor may explore: Changing antidepressants if sexual side effects are present Helpful if emotional or relationship factors are involved Sexual dysfunction can sometimes signal underlying health conditions, including: In some cases, reduced genital blood flow may mirror reduced blood flow elsewhere in the body. That's why sexual health changes shouldn't be ignored. If you're considering tadalafil, bring these questions to your appointment: Is tadalafil safe given my health history? Could hormones be contributing to my symptoms? Are there alternative treatments I should try first?
What side effects should I watch for? How will we monitor whether it's working? Your doctor may recommend blood tests, a cardiovascular check, or a hormone panel before prescribing anything. Tadalafil may offer benefits for some women aged 30–45 who struggle with physical aspects of sexual arousal. It is not FDA-approved for female sexual dysfunction It does not address emotional or hormonal causes It must be prescribed and monitored by a doctor If you're noticing changes in sexual function, don't ignore them—but don't panic either. in a cohort of 340 subjects (264
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Generic | 10mg | 20 Pills | 48.23€ 45.93€ | |
| Cialis Generic | 40mg | 30 + 4 Pills | 74.97€ 71.40€ | |
| Cialis Generic | 60mg | 10 Pills | 41.22€ 39.26€ | |
| Cialis Generic | 5mg | 30 + 4 Pills | 53.56€ 51.01€ | |
| Cialis Generic | 20mg | 90 + 6 Pills | 154.71€ 147.34€ | |
| Cialis Generic | 10mg | 30 + 4 Pills | 63.32€ 60.30€ | |
| Cialis Generic | 5mg | 120 + 6 Pills | 132.92€ 126.59€ | |
| Cialis Generic | 10mg | 60 + 6 Pills | 105.81€ 100.77€ | |
| Cialis Generic | 5mg | 270 + 10 Pills | 205.81€ 196.01€ | |
| Cialis Generic | 20mg | 270 + 10 Pills | 335.21€ 319.25€ | |
| Cialis Generic | 60mg | 30 + 2 Pills | 85.33€ 81.27€ | |
| Cialis Generic | 40mg | 180 + 10 Pills | 277.29€ 264.09€ | |
| Cialis Generic | 20mg | 20 Pills | 54.72€ 52.11€ | |
| Cialis Generic | 5mg | 10 Pills | 29.39€ 27.99€ |
females, 76 males).3 Clinical worsening was defined as
There was a trend toward a female age-dependent effect in change in 6MWD; the premenopausal group showed the greatest improvement. A significant sex- or age-dependent effect on TCW was not present. In conclusion, this retrospective analysis of the PHIRST trial suggests that men and premenopausal women may experience greater functional improvement when treated with tadalafil than older women, but there was no consistent sex or menopausal effect on TCW. Keywords: pulmonary arterial hypertension, sex differences, tadalafil, 6-minute walk distance, menopause Pulmonary arterial hypertension (PAH) is a group of disorders that are characterized by elevated pulmonary arterial resistance, leading to eventual right heart failure.1,2 PAH is a female-predominate disease; according to the REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) Registry, group 1 PAH is four times more likely in female patients than in male patients.3-6 While the exact cause of the observed female predominance is unknown, it may potentially relate to a disruption in the protective effect of estrogen on the pulmonary vasculature and myocardium.7-11 A recent study examining patient factors as a predictor of treatment response with tadalafil found male sex to be predictive of improved change in 6-minute walk distance (6MWD).12 Despite this, there is a buy tadalafil paucity of literature investigating the effect of menopause on response to PAH treatment. Providing more tailored therapy to patients may allow for more cost-conscious, targeted, and safer treatment for patients with PAH.
Two prior sex-specific treatment response studies found opposing results for response to tadalafil and endothelin receptor antagonists (ERAs). ERAs have demonstrated a more robust change in 6MWD in female patients, while tadalafil has demonstrated a significant increase in 6MWD in male patients.12,13 The etiology of this sex difference between the treatment agents is unknown and could possibly involve differences in nitric oxide (NO) and endothelin signaling between the sexes.14,15 Multiple animal studies have demonstrated that estrogen decreases pulmonary arterial vasoconstriction by decreasing expression of endothelin 1 and increasing release of NO and prostaglandin.8,16-20 Neither of these studies addressed the effect of menopause on treatment response or evaluated time to clinical worsening (TCW) as a clinical end point. In the general population, many vasoreactive conditions, such as migraine headache and Raynaud’s phenomenon, increase after menopause.17 This postmenopausal increase is also demonstrated in PAH and is postulated to be due to estrogen withdrawal, as it has been demonstrated in animal models that lower estrogen and progesterone states produce increased pulmonary vasoconstriction.17,21-24 Despite the known effects of estrogen on the pulmonary vasculature, it remains unclear how menopause affects response to treatment of PAH in general, including with phosphodiesterase type 5 (PDE-5) inhibitors. A treatment agent with a postmenopausal-specific treatment benefit would be extremely valuable given the high prevalence of PAH in this population compared with that in men and younger women. Tadalafil is a commonly prescribed and well-tolerated PDE-5 inhibitor.
Multiple studies have indicated that treatment with PDE-5 inhibitors improves outcomes in PAH, but none have reported any sex-specific or menopausal status–specific treatment effects on TCW.2,3 Our present study examines sex-specific treatment responses to tadalafil by assessing change in 6MWD and TCW using data from the pivotal randomized, placebo-controlled Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) trial.3 We also report the effects of menopausal status on treatment response to tadalafil using age as a surrogate for menopausal status. Patient selection included those enrolled in the PHIRST study.3 For the purposes of this study, deidentified information was used, and therefore a separate institutional review board was not required. For the initial PHIRST study, the local institutional review boards or independent ethics committees approved the protocol, and written consent was obtained from all patients.3 Subjects were at least 12 years of age and had symptomatic PAH (the youngest male was 19 years old; the youngest female was 14 years old). Subjects exposed to anorexigens or given a diagnosis of connective tissue disease, HIV infection, congenital pulmonary shunts, or idiopathic PAH were included in this study. The hemodynamic criteria for PAH included mean pulmonary arterial pressure of ≥25 mmHg, pulmonary arterial wedge pressure of ≤15 mmHg, and pulmomary vascular resistance of ≥3 Wood units. death, lung or heart-lung transplantation, atrial septostomy,
hospitalization due to worsening PAH, initiation of
new PAH-approved therapy, or worsening World Health
| Drug | Mechanism | Duration of Action | Side Effects | Ease of Use | Off-label Evidence |
|---|---|---|---|---|---|
| Tadalafil | PDE5 inhibitor | Up to 36 hours | Headache, flushing | Oral daily | Moderate |
| Sildenafil (Viagra) | PDE5 inhibitor | 4-6 hours | Visual disturbances | Oral as needed | Limited in women |
| Vardenafil | PDE5 inhibitor | 4-6 hours | Headache, dizziness | Oral as needed | Experimental |
Organization (WHO) functional class over the 16 weeks.
Patients with a 6MWD of <150 or >450 m were excluded. Patients treated with intravenous epoprostenol, inhaled or intravenous iloprost, or subcutaneous or intravenous treprostinil were excluded. Patients taking a maximum dose of bosentan (125 mg) twice daily for a minimum of 12 weeks at the time of screening continued to receive bosentan in addition to the study medicine. In total, 405 subjects (317 females, 88 males) were enrolled in a 16-week, double-blind, double-dummy, placebo-controlled multicenter study. Subjects were randomized into groups receiving placebo or 2.5, 10, 20, or 40 mg of tadalafil once daily.